17 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/17/2899667/0/en/Mustang-Bio-Announces-Favorable-Efficacy-and-Safety-Data-from-Complete-Waldenstrom-Macroglobulinemia-Cohort-of-Phase-1-2-Clinical-Trial-of-MB-106-CD20-Targeted-Autologous-CAR-T-The.html
LOOKING FOR A SUPPLIER?